|Feb 4, 2005||
OXiGENE's CA4P Demonstrates Anti-tumor Activity in Preclinical Retinoblastoma Model- Study Published in Investigative Ophthalmology & Visual Science -
WALTHAM, Mass.--(BUSINESS WIRE)--Feb. 4, 2005--OXiGENE, Inc. (NASDAQ: OXGN, XSSE: OXGN) announced today the publication of a preclinical study using local administration of Combretastatin A4P (CA4P) in the treatment of a murine model of retinoblastoma. The study reported that a subconjunctival delivery of CA4P, a vascular targeting agent (VTA)...
|Jan 7, 2005||
OXiGENE Announces Corporate Goals for 2005: Company Plans to Move CA4P into Later-stage Clinical Studies in Two Cancer Indications in 2005
WALTHAM, Mass.--(BUSINESS WIRE)--Jan. 7, 2005--OXiGENE, Inc. (Nasdaq: OXGN, XSSE: OXGN), developing novel small-molecule therapeutics to treat cancer and certain eye diseases, today announced its corporate goals for 2005. "We believe we are entering 2005 in th...